Related Experiment Videos
Superantigen-induced lysis of melanoma cells
1Department of Oncology and Hematology, Children's University Hospital, Tübingen, Germany.
Abstract:
Superantigens like the Staphylococcus enterotoxin A (SEA) can direct cytotoxic T lymphocytes expressing certain T cell receptor V beta regions to lyse MHC class II-positive target cells. This superantigen-dependent cellular cytotoxicity (SDCC) has been extended to MHC class II-negative tumour cells by targeting T cells via conjugates of a tumour-specific monoclonal antibody (moAb) and a superantigen. In the present study the MHC class II-negative human melanoma cell lines G361 and MaRI were tested for susceptibility to SDCC in vitro. Antibodies recognizing the disialoganglioside GD3 and the CD10 antigen were linked to SEA either by a recombinant protein A-SEA fusion protein or an anti-kappa moAb-SEA chemical conjugate. Specific lysis of melanoma cells was dose- and effector to target (E:T) cell ratio-dependent. Introduction of a point mutation into the SEA gene (producing SEAm9) in order to reduce MHC II affinity of the superantigen, which has already been shown to severely diminish superantigen-dependent binding and lysis of MHC class II-positive cells, did not influence antibody-targeted SDCC. Cytotoxicity was equal with both antibodies (anti-GD3 and anti-CD10) and independent of whether protein A-SEA, protein A-SEAm9 or anti-kappa-SEA were used.
Insights
Antibody-targeted superantigen-dependent cellular cytotoxicity (SDCC) effectively lyses MHC class II-negative melanoma cells. This approach bypasses the need for superantigen affinity to MHC class II, offering a promising cancer therapy strategy.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Superantigens like Staphylococcus enterotoxin A (SEA) mediate T cell-dependent lysis of MHC class II-positive cells.
- Superantigen-dependent cellular cytotoxicity (SDCC) can be adapted for MHC class II-negative tumor cells using antibody-superantigen conjugates.
Purpose of the Study:
- To evaluate the efficacy of antibody-targeted SDCC against MHC class II-negative human melanoma cell lines.
- To investigate the role of superantigen affinity for MHC class II in antibody-targeted SDCC.
Main Methods:
- Conjugation of anti-GD3 or anti-CD10 antibodies to SEA or a mutated SEA (SEAm9) via protein A fusion or chemical linkage.
- In vitro assessment of SDCC against G361 and MaRI melanoma cell lines.
- Analysis of dose- and effector-to-target (E:T) cell ratio-dependent cytotoxicity.
Main Results:
- Antibody-targeted SDCC demonstrated specific lysis of MHC class II-negative melanoma cells in a dose- and E:T ratio-dependent manner.
- A mutated SEA (SEAm9) with reduced MHC II affinity did not impair antibody-targeted SDCC efficacy.
- Cytotoxicity was consistent across different antibody specificities (anti-GD3, anti-CD10) and conjugation methods (protein A-SEA, protein A-SEAm9, anti-kappa-SEA).
Conclusions:
- Antibody-targeted SDCC is a viable strategy for eliminating MHC class II-negative melanoma.
- The efficacy of this approach is independent of the superantigen's affinity for MHC class II molecules.